Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 2/20 | 0.69 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.69 |
| ▸ | EGFR | P00533 | 1/20 | 0.69 |
| ▸ | CDK2 | P24941 | 1/20 | 0.69 |
| ▸ | KDR | P35968 | 1/20 | 0.69 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.69 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.69 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.69 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.69 |
| ▸ | AURKB | Q96GD4 | 15/20 | 0.56 |
| ▸ | AURKA | O14965 | 14/20 | 0.56 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13154943 | 0.82 | LCK (1.00) | LCKCHEK1EGFRCDK2KDR | |
| SCHEMBL13155379 | 0.81 | LCK (0.62) | LCKCHEK1EGFRCDK2KDR | |
| SCHEMBL13155392 | 0.80 | LCK (0.70) | LCKCHEK1EGFRCDK2KDR | |
| SCHEMBL13155382 | 0.80 | LCK (0.70) | LCKCHEK1EGFRCDK2KDR | |
| SCHEMBL13155399 | 0.79 | LCK (0.64) | LCKCHEK1EGFRCDK2KDR | |
| SCHEMBL13155389 | 0.77 | LCK (0.64) | LCKCHEK1EGFRCDK2KDR | |
| SCHEMBL14507449 | 0.73 | LCK (0.62) | LCKCHEK1EGFRCDK2KDR | |
| SCHEMBL13155357 | 0.72 | AURKB (1.00) | LCKCHEK1EGFRCDK2KDR | |
| SCHEMBL13154944 | 0.72 | AURKB (1.00) | LCKCHEK1EGFRCDK2KDR | |
| SCHEMBL13154947 | 0.72 | LCK (0.81) | LCKCHEK1EGFRCDK2KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100249030-A1 | ANTI-MITOTIC AGENT AND AURORA KINASE INHIBITOR COMBINATION AS ANTI-CANCER TREATMENT | SCHERING CORPORATION | 2010-09-30 | — | — | US | disclosed |
| US-20100249030-A1 | ANTI-MITOTIC AGENT AND AURORA KINASE INHIBITOR COMBINATION AS ANTI-CANCER TREATMENT | SCHERING CORPORATION | 2010-09-30 | — | — | US | disclosed |
| US-7511040-B2 | Imidazopyrazines as protein kinase inhibitors | SCHERING CORPORATION (US) | 2009-03-31 | — | — | US | disclosed |
| US-7511040-B2 | Imidazopyrazines as protein kinase inhibitors | SCHERING CORPORATION (US) | 2009-03-31 | — | — | US | disclosed |
| WO-2009017701-A2 | ANTI-MITOTIC AGENT AND AURORA KINASE INHIBITOR COMBINATION AS ANTI-CANCER TREATMENT | SCHERING CORPORATION (US) | 2009-02-05 | — | — | WO | disclosed |
| US-20080139571-A1 | IMIDAZOPYRAZINES AS PROTEIN KINASE INHIBITORS | SCHERING CORPORATION | 2008-06-12 | — | — | US | disclosed |
| US-20080139571-A1 | IMIDAZOPYRAZINES AS PROTEIN KINASE INHIBITORS | SCHERING CORPORATION | 2008-06-12 | — | — | US | disclosed |
| WO-2008057512-A2 | IMIDAZOPYRAZINES AS PROTEIN KINASE INHIBITORS | SCHERING CORPORATION (US) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249030-A1 | ANTI-MITOTIC AGENT AND AURORA KINASE INHIBITOR COMBINATION AS ANTI-CANCER TREATMENT | AURKC, AURKA, AURKB | LCK 732/4885CHEK1 61/4885EGFR 1732/4885 |
| US-20080139571-A1 | IMIDAZOPYRAZINES AS PROTEIN KINASE INHIBITORS | AURKC, AURKA, AURKB | LCK 110/4885CHEK1 35/4885EGFR 800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.